VU661013

selective MCL1 inhibitor

Also Known As:

3-((4R)-7-chloro-10-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-4-methyl-1-oxo-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-3,4-dihydropyrazino(1,2-a)indol-2(1H)-yl)-1-methyl-1H-indole-5-carboxylic acid

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - VU661013: 1
  - Pyrazines: 150
    - VU661013: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - VU661013: 1

Experts

1.	Cook, Rebecca S: 1 article (09/2019)
2.	Elion, David L: 1 article (09/2019)
3.	Hicks, Donna J: 1 article (09/2019)
4.	Rahman, Bushra: 1 article (09/2019)
5.	Sanchez, Violeta: 1 article (09/2019)
6.	Williams, Michelle M: 1 article (09/2019)

Related Diseases

1.	Neoplasms (Cancer) 09/10/2019 - "Similarly, combined use of the selective Mcl-1 inhibitor VU661013 with ABT-263 resulted in tumor cell apoptosis and diminished tumor growth in vivo. "

Related Drugs and Biologics

1.	navitoclax